High concentration anti-c5 antibody formulations

A stable aqueous solution comprising:

• (a) an anti-C5 antibody, wherein the anti-C5 antibody comprises a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:
• 19, a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:
• 18, a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:3, a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:4, a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:5, and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:6;
• (b) about 50 mM Phosphate Buffer;
• (c) about 5% sucrose;
• (d) about 0.05% Polysorbate 80;
• and
• (e) about 25 mM Arginine.

A stable aqueous solution comprising:

• (a) an anti-C5 antibody at a concentration of about 100 mg/mL, wherein the anti-C5 antibody comprises a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:
• 19, a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:
• 18, a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:3, a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:4, a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:5, and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:6;
• (b) about 50 mM Phosphate Buffer;
• (c) about 5% sucrose;
• and
• (d) about 25 mM Arginine.

A stable aqueous solution comprising:

• (a) an anti-C5 antibody at a concentration of about 70 mg/mL, wherein the anti-C5 antibody comprises a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:19, a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:18, a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:3, a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:4, a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:5, and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:6;
• (b) about 50 mM Phosphate Buffer;
• (c) about 5% sucrose;
• and
• (d) about 25 mM Arginine.

A stable aqueous solution comprising:

• (a) ravulizumab at a concentration of about 100 mg/mL;
• (b) about 50 mM phosphate;
• (c) about 100 mg/mL sucrose;
• (d) about 0.05% Polysorbate 80;
• and
• (e) about 25 mM L-Arginine.